Advent France Biotechnology focuses on ground-breaking innovations in Life Sciences to address unmet medical and clinical needs, building the next generation of pioneering healthcare companies.
Employees: 11-50
Portfolio 1
| Date | Name | Website | Total Raised | Location |
| 24.07.2020 | ARTHEx Bio... | arthexbiotech.com | $138.32M | Spain |
News 28
Show more
Mentions in press and media 10
| Date | Title | Description |
| 02.12.2021 | Integra Tx cierra una ronda de €4,5M a la que han acudido Advent France Biotechnology, Invivo Capital y Takeda Ventures | 02/12/2021 Nota de prensa INTEGRA TX CIERRA UNA RONDA DE €4,5M CON ADVENT FRANCE BIOTECHNOLOGY, INVIVO CAPITAL Y TAKEDA VENTURES. La biotecnológica, especializada en edición genética y fundada por los investigadores Marc Güell y Avencia ... |
| 02.12.2021 | Integra Tx secures €4.5M in funding from Advent France Biotechnology, Invivo Capital and Takeda Ventures | 02/12/2021 Press release INTEGRA TX SECURES €4.5 MILLION IN FUNDING FROM ADVENT FRANCE BIOTECHNOLOGY, INVIVO CAPITAL AND TAKEDA VENTURES. The biotechnology company, which specialises in gene editing and was founded by researchers Marc Gü... |
| 01.12.2021 | Integra Tx secures €4.5-million in funding from Advent France Biotechnology, Invivo Capital and Takeda Ventures | - |
| 30.09.2021 | Advent France Biotechnology launches its second fund with a first close at €86M ($102M) | - |
| 30.09.2021 | Advent France Biotechnology Launches Second Fund; Holds First Close at €86M | Advent France Biotechnology (AFB), a Paris, France-based regulated investment firm dedicated to life sciences, held the first closing of its second fund, at €86M ($102M). The European Investment Fund (EIF) and the Fonds national d’amorçage ... |
| 24.07.2020 | Arthex Biotech capta €4,25 millones de Invivo Ventures y Advent France Biotechnology | 24/07/2020 Nota de prensa ARTHEX BIOTECH CAPTA €4,25 MILLONES DE INVIVO VENTURES Y ADVENT FRANCE BIOTECHNOLOGY. La financiación permitirá a la empresa avanzar en el desarrollo de su terapia para la distrofia miotónica Arthex Biotech (AR... |
| 24.07.2020 | Arthex secures €4.25M from Invivo Ventures and Advent France Biotechnology | 24/07/2020 Press Release ARTHEX SECURES €4.25M FROM INVIVO VENTURES AND ADVENT FRANCE BIOTECHNOLOGY. Funding will help advance development of company’s Myotonic Dystrophy therapy Arthex Biotech (ARTHEx), a preclinical stage life science... |
| 09.01.2020 | Alderaan Biotechnology Secures €18.5M in Series A Funding | Alderaan Biotechnology, a Paris, France-based preclinical stage company focused on monoclonal antibodies development for the treatment of cancer, completed a Series A funding of €18.5M ($20.7M). Backers included investors Advent France Biot... |
| 28.04.2017 | Advent France Biotechnology Holds First Close of Biotechnology Fund I, at €64.75M | Paris, France based Advent France Biotechnology has held the first close of Advent France Biotechnology Seed-Fund I, at €64.75m (USD68.5m). Supported in by the National Seed-Fund (Fonds National d’Amorçage) managed by Bpifrance under the In... |
| 20.04.2017 | Advent France Biotechnology launches its first Life Sciences seed-fund with a first closing at €64.75M (USD68.5M) | - |